The Search for Cancer Diagnostic Markers: A Race Against Time - The knowledge that early detection and treatment offers the best outcome for the patient has long driven the search for effective diagno


The Search for Cancer Diagnostic Markers: A Race Against Time
The knowledge that early detection and treatment offers the best outcome for the patient has long driven the search for effective diagnostics.

BioPharm International

11. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005; 36(2):195-201.

12. Matsuzaki H, Kobayashi H, Yagyu T, Wakahara K, Kondo T, Kurita N,et al. Plasma bikunin as a favorable prognostic factor in ovarian cancer. J Clin Oncol. 2005; 23(7):1463-72.

13. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S113-9.

14. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson,PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods. 2001; 248(1-2):47-66.

15. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C. Syndecan-1 Expression - A Novel Prognostic Marker in Pancreatic Cancer. Oncology 2005; 68(2-3):97-106.

16. Seregni E, Coli A, Mazzucca N, Italian Group RIA-IRMA Test, Italian Association of Nuclear Medicine. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 2004; 31 (Suppl 1):S15-22.

17. Lai IR, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002; 49(46):1157-60.

18. Saad F. UPM3: review of a new molecular diagnostic urine test for prostate cancer. Can J Urol. 2005 Feb;12 Suppl 1:40-3; discussion 99-100.

19. Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003 Jun;24(6):715-35.

20. Mehta K, Haller JO, Legasto AC. Imaging neuroblastoma in children.Crit Rev Comput Tomogr. 2003;44(1):47-61.

21. Ardekani AM, Liotta LA, Petricoin EF 3rd. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn. 2002 Jul;2(4):312-20.

22. Gamzu R, Almog B, Levin I, Fainaru O, Niv J, Lessing JB, Bar-Am A. Clinical and economic implications of adding HPV tests to the routine cytology follow-up and management of patients with histologically defined cervical intraepithelial neoplasia grade 1 Gynecol Oncol. 2002 Aug;86(2):129-33.

23. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging. 2004 Jun;48(2):119-42.

24. Wilkinson NW, Loewen GM, Klippenstein DL, Litwin AM, Anderson TM. The evolution of lung cancer screening. J Surg Oncol. 2003 Dec;84(4):234-8.

25. Xing PX, Young GP, Ho D, Sinatra MA, Hoj PB, McKenzie IF. A new approach to fecal occult blood testing based on the detection of haptoglobin. Cancer. 1996 Jul 1;78(1):48-56.

26. Kocak H, Oner-Iyidogan Y, Kocak T, Oner P. Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Biochem. 2004 Aug;37(8):673-8.

27. Pattari SK, Dey P. Urine: beyond cytology for detection of malignancy. Diagn Cytopathol. 2002 Sep;27(3):139-42.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here